Immunesensor Therapeutics Inc.
Clinical trials sponsored by Immunesensor Therapeutics Inc., explained in plain language.
-
Cancer trial halted: experimental combo shows promise but stops short
Disease control TerminatedThis study tested whether adding an experimental drug (IMSA101) to standard immunotherapy and a special type of radiation (PULSAR) could help control cancer in people with non-small cell lung cancer or kidney cancer that had spread to a few places. Only 6 people enrolled before t…
Phase: PHASE2 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Cancer combo trial halted early: did the STING drug fall short?
Disease control TerminatedThis study tested whether adding an experimental drug called IMSA101 to a combination of targeted radiation and immunotherapy could help control cancers that were slowly progressing despite prior treatment. The trial enrolled 16 adults with various solid tumors that had up to 6 g…
Phase: PHASE2 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC